A panel of medical experts discuss key highlights from ASCO GI 2024 surrounding the hepatocellular carcinoma (HCC) treatment landscape.
EP. 1: Hepatocellular Carcinoma (HCC) Disease State Overview
Anthony El-Khoueiry, MD, opens the discussion by defining the current prevalence of hepatocellular carcinoma (HCC).
EP. 2: Utilizing Interventional Radiology and Liver-directed Therapies
Mechanism of action for liver-directed therapies in HCC are illustrated by Anne Covey, MD, an interventional radiologist.
EP. 3: Determining Transarterial Chemoembolization (TACE) Candidacy for Patients with HCC
Michael Morse, MD, establishes his criteria for implementing TACE versus systemic therapy in HCC treatment.
EP. 4: EMERALD-1 Study: Significance as Presented at ASCO GI 2024
Rachna Shroff, MD, MS, FASCO, highlights the prominence of the EMERALD-1 study for patients with HCC.
EP. 5: EMERALD-1 Study: Outshining Negative Clinical Trials Based Upon TKI- and Liver-directed Therapies
Drs Gong and Covey emphasize the impact of TACE + durvalumab ± bevacizumab combination therapy surrounding HCC treatment strategy.
EP. 6: IMBrave-050 Study Overview
Dr Shroff breaks down the combination of atezolizumab and bevacizumab as outlined by the IMBrave-050 study.
EP. 7: Patient Profile 1: Advanced HCC Treated with Durvalumab and Tremelimumab
Medical experts provide insight into managing treatment of advanced HCC through the lens of a patient profile.
EP. 8: HIMALAYA Study in Advanced Stage HCC
A comprehensive discussion of the HIMALAYA study, evaluating the STRIDE regimen of durvalumab plus tremelimumab in first-line treatment for advanced HCC.
EP. 9: Establishing Optimal HCC Treatment Strategy
Anwaar Saeed, MD, provides comprehensive insight into the HCC treatment selection process.
EP. 10: IMBrave150 Study Overview
Dr Gong breaks down the structure and key takeaways from the IMBrave150 study.
EP. 11: HCC Treatment Strategy Driven by Real-World Evidence
Real-world evidence (RWE) provides critical knowledge for providers constructing a treatment regimen for patients diagnosed with hepatocellular carcinoma.
EP. 12: Combining Liver-directed and Systemic Therapies in HCC
The impact of compounding liver-directed and systemic therapies in HCC management is discussed by Drs Morse and Covey.
EP. 13: Patient Profile 2: Patient Progression After Frontline HCC Therapy
Drs Saeed and Shroff discuss the next patient profile, focusing on HCC treatment strategies following disease progression after first-line therapy.
EP. 14: CARES-310 Trial: Impressions and Clinical Impact on HCC Treatment Landscape
Key opinion leaders share their takeaways from the CARES-310 trial and its impact on their treatment approach in HCC management.
EP. 15: REGONEXT Study: Driving Second-line HCC Treatment Strategy
Dr Morse discusses key takeaways from the REGONEXT study presented at ASCO GI 2024.
EP. 16: Trajectory of Evolving HCC Treatment Landscape
The expert panelists provide their final insights surrounding the future of HCC treatment management.
Perioperative Vorasidenib and Ivosidenib Remain Effective, Safe in IDH1+ Diffuse Glioma
Mirdametinib Improves HRQOL in Adult and Pediatric Patients With NF1-PN
Dr Kumethaker on CSF Tumor Detection in Breast Cancer or NSCLC with Leptomeningeal Disease
Dr Schiff on PFS and OS Data With Temozolomide Plus Radiation in Grade II Glioma